BioLineRx to Report First Quarter 2026 Results on May 27, 2026
BioLineRx (NASDAQ: BLRX) will report unaudited Q1 2026 results on May 27, 2026, before U.S. markets open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioLineRx (NASDAQ: BLRX) will report unaudited Q1 2026 results on May 27, 2026, before U.S. markets open. Management will host a conference call at 8:30 a.m. EDT with CEO Philip Serlin, accessible via phone, live webcast, and replay.
Details
News Market Reaction – BLRX
On May 20, the day this news came out, BLRX closed 4.56% above the previous close.
Data tracked by StockTitan Argus for the May 20 session.
Key Figures
- Earnings release date
- May 27, 2026
- Unaudited Q1 2026 results release before U.S. market open
- Quarter end date
- March 31, 2026
- Quarter for which results will be reported
- Conference call time
- 8:30 a.m. EDT
- Management call discussing Q1 2026 results
- US dial-in
- +1-888-407-2553
- Participant number for U.S. investors
- International dial-in
- +972-3-918-0685
- Participant number for international investors
- Replay end date
- May 28, 2026
- Dial-in replay availability for the conference call
Previous Earnings date Reports
-
Set date and call details for release of 2025 annual results.
-
Announced timing and conference call for Q3 2025 results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management to Hold Conference Call at 8:30 a.m. EDT
The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.
To access the conference call, please dial +1-888-407-2553 from the
About BioLineRx
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.
The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.
CONTACTS:
Chuck Padala
LifeSci Advisors, LLC
IR@biolinerx.com
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026-302777565.html
SOURCE BioLineRx Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.